RATIONALE: Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control. OBJECTIVE: To determine the safety and immunogenicity of MVA85A, a novel TB vaccine, among M.tb- and/or HIV-infected persons in a setting where TB and HIV are endemic. METHODS: An open-label, phase IIa trial was conducted in 48 adults with M.tb and/or HIV infection. Safety and immunogenicity were analyzed up to 52 weeks after intradermal vaccination with 5 × 10(7) plaque-forming units of MVA85A. Specific T-cell responses were characterized by IFN-γ enzyme-linked immunospot and whole blood intracellular cytokine staining assays. MEASUREMENTS AND MAIN RESULTS: MVA85A was well tolerated and no vaccine-related serious adverse events were recorded. MVA85A induced robust and durable response of mostly polyfunctional CD4(+) T cells, coexpressing IFN-γ, tumor necrosis factor-α, and IL-2. Magnitudes of pre- and postvaccination T-cell responses were lower in HIV-infected, compared with HIV-uninfected, vaccinees. No significant effect of antiretroviral therapy on immunogenicity of MVA85A was observed. CONCLUSIONS: MVA85A was safe and immunogenic in persons with HIV and/or M.tb infection. These results support further evaluation of safety and efficacy of this vaccine for prevention of TB in these target populations.
RATIONALE: Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control. OBJECTIVE: To determine the safety and immunogenicity of MVA85A, a novel TB vaccine, among M.tb- and/or HIV-infectedpersons in a setting where TB and HIV are endemic. METHODS: An open-label, phase IIa trial was conducted in 48 adults with M.tb and/or HIV infection. Safety and immunogenicity were analyzed up to 52 weeks after intradermal vaccination with 5 × 10(7) plaque-forming units of MVA85A. Specific T-cell responses were characterized by IFN-γ enzyme-linked immunospot and whole blood intracellular cytokine staining assays. MEASUREMENTS AND MAIN RESULTS: MVA85A was well tolerated and no vaccine-related serious adverse events were recorded. MVA85A induced robust and durable response of mostly polyfunctional CD4(+) T cells, coexpressing IFN-γ, tumor necrosis factor-α, and IL-2. Magnitudes of pre- and postvaccination T-cell responses were lower in HIV-infected, compared with HIV-uninfected, vaccinees. No significant effect of antiretroviral therapy on immunogenicity of MVA85A was observed. CONCLUSIONS: MVA85A was safe and immunogenic in persons with HIV and/or M.tbinfection. These results support further evaluation of safety and efficacy of this vaccine for prevention of TB in these target populations.
Authors: Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Fatima Isaacs; Alana Keyser; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Anthony Hawkridge; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Helen McShane; Willem A Hanekom Journal: Eur J Immunol Date: 2010-01 Impact factor: 5.532
Authors: Hans-Willi Mittrücker; Ulrich Steinhoff; Anne Köhler; Marion Krause; Doris Lazar; Peggy Mex; Delia Miekley; Stefan H E Kaufmann Journal: Proc Natl Acad Sci U S A Date: 2007-07-18 Impact factor: 11.205
Authors: Barbara Kalsdorf; Thomas J Scriba; Kathryn Wood; Cheryl L Day; Keertan Dheda; Rodney Dawson; Willem A Hanekom; Christoph Lange; Robert J Wilkinson Journal: Am J Respir Crit Care Med Date: 2009-09-24 Impact factor: 21.405
Authors: Kathryn T Whelan; Ansar A Pathan; Clare R Sander; Helen A Fletcher; Ian Poulton; Nicola C Alder; Adrian V S Hill; Helen McShane Journal: PLoS One Date: 2009-06-16 Impact factor: 3.240
Authors: Susan L Baldwin; Lance K Ching; Samuel O Pine; Magdalini Moutaftsi; Elyse Lucas; Aarthy Vallur; Mark T Orr; Sylvie Bertholet; Steven G Reed; Rhea N Coler Journal: J Immunol Date: 2013-07-31 Impact factor: 5.422
Authors: Benjamin M Kagina; Nazma Mansoor; Eloi P Kpamegan; Adam Penn-Nicholson; Elisa Nemes; Erica Smit; Sebastian Gelderbloem; Andreia P Soares; Brian Abel; Alana Keyser; Mzwandile Sidibana; Jane E Hughes; Gilla Kaplan; Gregory D Hussey; Willem A Hanekom; Thomas J Scriba Journal: J Immunol Methods Date: 2014-12-16 Impact factor: 2.303
Authors: Mark Hatherill; Hendrik Geldenhuys; Bernadette Pienaar; Sara Suliman; Phalkun Chheng; Sara M Debanne; Daniel F Hoft; W Henry Boom; Willem A Hanekom; John L Johnson Journal: Vaccine Date: 2014-05-09 Impact factor: 3.641